Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PharmaCore Biotech
Tainan, Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
PharmaCore Biotech currently has two active pipeline programs in Phase 2 clinical trials: odatroltide (a free radical inhibitor) for acute ischemic stroke and alcestobart (an anti-LAG3 monoclonal antibody) for advanced malignant neoplasms. Early clinical results demonstrate advancing safety and efficacy assessments in their respective indications, with at least one multicenter randomized controlled Phase 2 trial ongoing for stroke.
- Therapeutic areas
- OncologyCardiovascularEndocrinologyNeurology
- Modalities
- Small moleculeMonoclonal antibody
- Industry
- Biotech
02
Partnerships
Lumosa TherapeuticsNanjing Leads Biolabs
Beyond the preview
Go deeper on PharmaCore Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaCore Biotech.